 Odds Ratio
"Odds Ratio" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
| Descriptor ID |
D016017
|
| MeSH Number(s) |
E05.318.740.600.600 G17.680.500 N05.715.360.750.625.590 N06.850.520.830.600.600
|
| Concept/Terms |
Odds Ratio- Odds Ratio
- Odds Ratios
- Risk Ratio
- Ratio, Risk
- Ratios, Risk
- Risk Ratios
- Relative Odds
- Odds, Relative
- Cross-Product Ratio
- Cross Product Ratio
- Cross-Product Ratios
- Ratio, Cross-Product
- Ratios, Cross-Product
|
Below are MeSH descriptors whose meaning is more general than "Odds Ratio".
Below are MeSH descriptors whose meaning is more specific than "Odds Ratio".
This graph shows the total number of publications written about "Odds Ratio" by people in this website by year, and whether "Odds Ratio" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 2 | 2 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 3 | 3 | | 1994 | 0 | 3 | 3 | | 1996 | 0 | 6 | 6 | | 1997 | 0 | 8 | 8 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 5 | 5 | | 2000 | 0 | 7 | 7 | | 2001 | 0 | 17 | 17 | | 2002 | 0 | 8 | 8 | | 2003 | 1 | 14 | 15 | | 2004 | 0 | 12 | 12 | | 2005 | 0 | 15 | 15 | | 2006 | 0 | 17 | 17 | | 2007 | 0 | 21 | 21 | | 2008 | 0 | 30 | 30 | | 2009 | 0 | 19 | 19 | | 2010 | 0 | 28 | 28 | | 2011 | 0 | 36 | 36 | | 2012 | 0 | 32 | 32 | | 2013 | 0 | 29 | 29 | | 2014 | 0 | 39 | 39 | | 2015 | 0 | 27 | 27 | | 2016 | 0 | 36 | 36 | | 2017 | 0 | 30 | 30 | | 2018 | 0 | 16 | 16 | | 2019 | 0 | 7 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Odds Ratio" by people in Profiles.
-
Ross KW, Stoeger CG, Rosenwasser GOD, O'Brien RC, Szczotka-Flynn LB, Ayala AR, Maguire MG, Benetz BA, Dahl P, Drury DC, Dunn SP, Farazdaghi SM, Hoover CK, Macsai MS, Mian SI, Nordlund ML, Penta JG, Soper MC, Terry MA, Verdier DD, Williams DV, Lass JH. Prelamellar Dissection Donor Corneal Thickness Is Associated With Descemet Stripping Automated Endothelial Keratoplasty Operative Complications in the Cornea Preservation Time Study. Cornea. 2019 Sep; 38(9):1069-1076.
-
Chow R, Aapro M, Navari RM, Gralla R, Chiu N, Chiu L, Chan S, Popovic M, Lam H, Lock M, DeAngelis C. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
-
Cerhan JR, Kane E, Vajdic CM, Linet MS, Monnereau A, Bernstein L, de Sanjose S, Chiu BC, Spinelli JJ, Maso LD, Zhang Y, Larrabee BR, Cozen W, Smith AG, Clavel J, Serraino D, Zheng T, Holly EA, Weisenberger DD, Slager SL, Bracci PM. Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Causes Control. 2019 Aug; 30(8):889-900.
-
Rodriguez SH, Peyton C, Lewis K, Andrews B, Greenwald MJ, Schreiber MD, Msall ME, Blair MP. Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019 06 01; 50(6):337-343.
-
Pierce BL, Tong L, Dean S, Argos M, Jasmine F, Rakibuz-Zaman M, Sarwar G, Islam MT, Shahriar H, Islam T, Rahman M, Yunus M, Lynch VJ, Oglesbee D, Graziano JH, Kibriya MG, Gamble MV, Ahsan H. A missense variant in FTCD is associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS Genet. 2019 03; 15(3):e1007984.
-
Pandey KR, Yang F, Cagney KA, Smieliauskas F, Meltzer DO, Ruhnke GW. The impact of marital status on health care utilization among Medicare beneficiaries. Medicine (Baltimore). 2019 Mar; 98(12):e14871.
-
Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019 01 04; 9(1):3.
-
Bryant AK, Sojourner EJ, Vitzthum LK, Zakeri K, Shen H, Nguyen C, Murphy JD, Califano JA, Cohen EEW, Mell LK. Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1393-1399.
-
Bleicher RJ, Chang C, Wang CE, Goldstein LJ, Kaufmann CS, Moran MS, Pollitt KA, Suss NR, Winchester DP, Tafra L, Yao K. Treatment delays from transfers of care and their impact on breast cancer quality measures. Breast Cancer Res Treat. 2019 Feb; 173(3):603-617.
-
Hambrick HR, Park SH, Schneider JA, Mayer KH, Carrico AW, Sherman SE, Duncan DT. Poppers and PrEP: Use of Pre-exposure Prophylaxis Among Men Who Have Sex with Men Who Use Inhaled Nitrites. AIDS Behav. 2018 Nov; 22(11):3658-3672.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|